grant
Deciphering the Interplay of Depleting Anti-PD-1 Antibodies and Autoimmune Environments in Type-1 Diabetes: Towards Better Utility of Therapeutic Antibody
Organization UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAHLocation SALT LAKE CITY, UNITED STATESPosted 19 Feb 2026Deadline 31 Jan 2031
NIHUS FederalResearch GrantFY2026Ab-mediated immunityAb-mediated protectionAccelerationAddressAdverse effectsAffectAffinotoxinsAfter CareAfter-TreatmentAftercareAgeAlbuminsAmendmentAntibodiesAntibody TherapyAntibody immunityAntibody protectionAntibody-drug conjugatesAntibody-mediated protectionAutoimmuneAutoimmune DiseasesAutoimmune ResponsesAutoimmune StatusAutoimmunityAutomobile DrivingB9 endocrine pancreasBrittle Diabetes MellitusCell BodyCellsCharacteristicsChronic DiseaseChronic IllnessClinicalCytotoxin-Antibody ConjugatesDevelopmentDiabetes MellitusDiseaseDisease ManagementDisorderDisorder ManagementEndocrine PancreasEnvironmentFamilyFc ReceptorFemaleFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryFoundationsGene ExpressionHyperglycemiaHyperglycemic MiceIDDMImmuneImmune responseImmunesImmunotoxinsInbred NOD MiceIndividualInsulin-Dependent Diabetes MellitusIslands of LangerhansIslets of LangerhansJuvenile-Onset Diabetes MellitusKetosis-Prone Diabetes MellitusLymphatic cellLymphocyteLymphocyticMediatingMediatorMiceMice MammalsMonoclonal Antibody-Toxin ConjugatesMurineMusNOD MouseNesidioblastsNon-Obese Diabetic MiceNonobese Diabetic MouseOutcomePD 1PD-1PD-1 antibodyPD1PD1 antibodyPancreatic IsletsPars endocrina pancreatisPathway interactionsPatientsPersonsPlayPopulationPre-Clinical ModelPreclinical ModelsPublic HealthR-Series Research ProjectsR01 MechanismR01 ProgramResearchResearch GrantsResearch Project GrantsResearch ProjectsRoleShapesSudden-Onset Diabetes MellitusT1 DMT1 diabetesT1DT1DMTestingTherapeuticTherapeutic antibodiesToxin-Antibody ConjugatesToxin-Antibody HybridsTreatment outcomeType 1 Diabetes MellitusType 1 diabetesType I Diabetes MellitusaPD-1aPD1agesanti programmed cell death 1anti-PD-1anti-PD-1 Abanti-PD-1 antibodiesanti-PD-1 monoclonal antibodiesanti-PD1anti-PD1 Abanti-PD1 antibodiesanti-PD1 monoclonal antibodiesanti-programmed cell death protein 1anti-programmed cell death protein 1 antibodiesanti-programmed death-1 antibodyantiPD-1antibody based therapiesantibody receptorantibody treatmentantibody-based therapeuticsantibody-based treatmentantibody-mediated immunityautoimmune conditionautoimmune disorderautoimmunity diseasebi-specific killer engagersbispecific killer cell engagerbispecific killer engagersbispecific natural killer engagercell typechronic disorderclinical developmentcombinatorialcomparativecytotoxicdesigndesigningdevelop therapydevelopmentaldiabetesdiabetogenicdrivingeffective therapyeffective treatmentflow cytophotometryhost responsehyperglycemicimmune system responseimmunoresponseimprovedinnovateinnovationinnovativeinsightinsulin dependent diabetesinsulin dependent type 1insulitisintervention developmentjuvenile diabetesjuvenile diabetes mellitusketosis prone diabeteslymph cellnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnon-obese diabetic (NOD) micenonobese diabetic (NOD) micenovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapypathwaypost treatmentpreservationprogrammed cell death 1programmed cell death protein 1programmed death 1protective effectpublic health relevanceresponsescRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsle2social rolesystemic lupus erythematosus susceptibility 2targeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapy developmenttreatment developmenttype I diabetestype one diabetesαPD-1αPD1♀
Description preview
PROJECT SUMMARY
This project aims to investigate the interactions and impacts between a depleting antibody (D-aPD-1) that targets
programmed death-1-expressing (PD-1+) cells and the autoimmune environment in type 1 diabetes (T1D). PD-
1+ cells are primarily effector lymphocytes that are diabetogenic in T1D.These PD-1+ cells could be a potential…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click